MET and liver cancer: Interestingly, LECT2 seems to be a tumor suppressor in liver cancer, and it has been reported that LECT2 inhibits HCC progression mediated the blockade of c-MET signaling (17), tumoral angiogenesis (18), oncogenic behaviors of cancer cells (15) and high-grade inflammation in HCC (19).